Vazonite - instructions for use, analogs, reviews and release forms (tablets prolonged retard 600 mg) of the drug for the treatment of circulatory disorders, ischemia in adults, children and pregnancy. Composition and alcohol

In this article, you can read the instructions for using the drug Vazonite. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Vasonit in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of the Vasonite in the presence of existing structural analogs.Use for the treatment of circulatory disorders, ischemia in adults, children, as well as during pregnancy and lactation. Composition and interaction of the drug with alcohol.

Vazonite is a xanthine derivative. Improves microcirculation in areas of impaired blood flow. Improves the rheological properties of blood (fluidity) due to the impact on the pathologically changed erythrocyte deformability, increases the elasticity of erythrocyte membranes, inhibits the aggregation of erythrocytes and platelets and reduces the increased viscosity of the blood. The mechanism of action of the drug is associated with the inhibition of phosphodiesterase and the accumulation of cAMP in the cells of the smooth muscles of the vessels and in the shaped elements of the blood.

Pentoxifylline (the active ingredient of the drug Vazonit) inhibits platelet and erythrocyte aggregation, reduces fibrinogen in the blood plasma and strengthens fibrinolysis, which leads to a decrease in blood viscosity and improvement of its rheological properties. Improves the supply of oxygen to tissues in areas of the circulatory system (including in the extremities, the central nervous system, and to a lesser extent - in the kidneys).

In the occlusive lesion of peripheral arteries (intermittent claudication) leads to an increase in walking distance, elimination of night cramps of gastrocnemius muscles, and reduction of pain at rest.When the cerebral circulation is disturbed, it improves the symptoms.

Has a weak myotropic vasodilating effect, somewhat reduces the OPSS and slightly dilates the coronary vessels.

Composition

Pentoxifylline + auxiliary substances.

Pharmacokinetics

When taking pills, Pentoxifylline is almost completely absorbed from the digestive tract. The prolonged form ensures continuous release of the active substance and its uniform absorption. Pentoxifylline is metabolized in the liver with the "first pass". Cmax pentoxifylline and its active metabolites is achieved after 3-4 hours and remains at the therapeutic level for about 12 hours. The drug is excreted predominantly (94%) by the kidneys in the form of metabolites. Excreted in breast milk. With severe renal dysfunction, excretion of metabolites is slowed down.

Indications

• violations of peripheral blood circulation against atherosclerotic, diabetic and inflammatory processes (including intermittent claudication caused by atherosclerosis, obliterating endarteritis, diabetic angiopathy);
• acute and chronic disorders of cerebral circulation of ischemic genesis;
• symptomatic treatment of the consequences of cerebral circulation disorders of atherosclerotic origin (attention deficit disorder, dizziness, memory impairment);
• atherosclerotic and discirculatory encephalopathy, angioneuropathy (paresthesia, Raynaud's disease);
• trophic tissue disorders due to violation of arterial or venous microcirculation (postthrombophlebitic syndrome, trophic ulcers, gangrene, frostbites);
• disorders of the blood circulation of the eye (acute and chronic circulatory insufficiency in the retina or choroid of the eye);
• disturbances in the function of the middle ear of vascular genesis, accompanied by deafness.

Forms of release

Tablets of prolonged action, coated with 600 mg (retard).

Instructions for use and dosing regimen

The drug is usually prescribed for 1 tablet (600 mg) 2 times a day (morning and evening). The maximum dose is 1.2 g.

Duration of treatment and dosing regimen is set by the doctor individually depending on the clinical picture of the disease and the therapeutic effect obtained.

Tablets should be taken orally, without chewing and drinking with a sufficient amount of liquid, preferably after eating.

In patients with chronic renal failure (CC less than 30 ml / min), the daily dose is reduced to 600 mg.

In patients with severe impairment of liver function, a dose reduction with regard to individual tolerability is necessary.

In patients with low blood pressure, as well as in patients at risk for possible reduction in blood pressure (patients with severe ischemic heart disease or with hemodynamically significant stenoses of cerebral vessels), treatment can be initiated in small doses. In these cases, the dose can be increased only gradually.

Side effect

• headache;
• dizziness;
• anxiety;
• sleep disorders;
• convulsions;
• cases of development of aseptic meningitis were noted;
• hyperemia of the facial skin;
• blood rushes to the skin of the face and upper chest;
• edema;
• increased brittleness of nails;
• nausea, vomiting;
• diarrhea;
• dry mouth;
• feeling of pressure and overflow in the stomach;
• decreased appetite;
• intestinal atony;
• exacerbation of cholecystitis;
• cholestatic hepatitis;
• pain in epigastrium;
• an increase in the activity of hepatic enzymes (ALT, AST, LDH) and AFP;
• scotoma;
• impaired vision;
• a decrease in blood pressure;
• tachycardia;
• progression of angina pectoris;
• arrhythmia;
• cardialgia;
• itching;
• hyperemia of the skin;
• hives;
• Quincke angioedema;
• anaphylactic shock;
• bleeding (from the vessels of the stomach, intestines, skin and mucous membranes);
• Thrombocytopenia, leukopenia, pancytopenia, hypofibrinogenemia, aplastic anemia.

Contraindications

• acute myocardial infarction;
• massive bleeding;
• acute hemorrhagic stroke;
• hemorrhage in the retina of the eye;
• pregnancy;
• lactation period (breastfeeding);
• age under 18 years (effectiveness and safety not established);
• hypersensitivity to the components of the drug;
• hypersensitivity to other methylxanthine derivatives.

Application in pregnancy and lactation

The use of the drug Vazonit during pregnancy and during breastfeeding is contraindicated.

Use in children

Contraindicated in children and adolescents under the age of 18 years (efficacy and safety not established).

Application in elderly patients

Older patients may need a dose reduction (increased bioavailability and reduced elimination rate).

special instructions

Patients with severe renal impairment in the treatment of Vasonitis should be under close medical supervision.In case of a hemorrhage in the retina of the eye during treatment with Vasonitis, the drug should be immediately discontinued.

Treatment should be carried out under the control of blood pressure. In patients with a low and unstable blood pressure, the dose should be reduced.

In patients with diabetes mellitus, who take hypoglycemic drugs, the use of vasonitis in large doses can cause the development of hypoglycemia (dose adjustment is required).

In case of simultaneous application of Vasonitis and anticoagulants, it is necessary to monitor the parameters of the blood coagulation system (including MNO).

For patients who have recently undergone surgery, systematic monitoring of hemoglobin and hematocrit is necessary.

Older patients may need a dose reduction (increased bioavailability and reduced elimination rate).

Smoking can reduce the therapeutic effectiveness of the drug.

During the intake of the drug is not recommended the use of alcohol and alcoholic beverages.

Impact on the ability to drive vehicles and manage mechanisms

Due to the possible appearance of dizziness, it is recommended to use caution when driving vehicles and servicing complex mechanisms.

Drug Interactions

Pentoxifylline may enhance the effect of drugs affecting the blood coagulation system (indirect and direct anticoagulants, thrombolytics), antibiotics (including cephalosporins - cefamandole, cefotetan, cefoperazone), valproic acid.

Increases the effectiveness of antihypertensive drugs, insulin and hypoglycemic agents for oral administration.

Cimetidine increases the concentration of the vasonite in the blood plasma (risk of side effects).

Co-administration with other xanthines can lead to excessive nervous excitement of patients.

In some patients, simultaneous use of pentoxifylline and theophylline may lead to an increase in theophylline concentration (risk of theophylline side effects).

Analogues of the drug Vazonite

Structural analogs for the active substance:

• Agapurin;
• Agapurin retard;
• Arbiflex;
• Pentamon;
• Pentylin;
• Pentylin forte;
• Pentohexal;
• Pentoxifylline;
• Pentomer;
• Radomine;
• Ralofect;
• Trenpental;
• Trental;
• Trental 400;
• Flexitale.

Similar medicines:

Other medicines: